Last reviewed · How we verify

NCT04674319

Attending to External Cues and Movement Strategies in Parkinson Disease

Completed NA Last updated 4 January 2022
What this trial tests

NA trial testing external cues and cogntive movement strategies in Parkinson Disease in 15 participants. Completed in 30 August 2021.

Timeline
1 March 2019
Primary endpoint
30 August 2020
30 August 2021

Quick facts

Lead sponsorGalit Yogev-Seligmann
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposebasic science
Enrollment15
Start date1 March 2019
Primary completion30 August 2020
Estimated completion30 August 2021
Sites1 location across Israel

Drugs / interventions tested

Conditions studied

Sponsor

Galit Yogev-Seligmann

Who can join

Adults 50 to 85, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

People with Parkinson's disease use compensatory strategies to overcome typical gait disturbances. These strategies rely on attentional mechanisms, however people with Parkinson disease suffer of decline in cognitive function. Therefore, the current study aims at exploring brain engagement and focus of attention process during walking with these compensatory strategies, in people with Parkinson disease. Such exploration would assist in understanding the feasibility of the compensatory strategies in daily lives of people with Parkinson's disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04674319.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing